Kiadis Poised To Launch Lead Product ATIR101 In 2019

 
• By Sten Stovall

Launch approval of Netherlands-based Kiadis Pharma's lead asset ATIR101 looks likely in Europe by early-2019 for safer, more effective bone marrow transplants. US approval will take longer.

Stem cells
ATIR101 is filed in Europe for haploidentical haematopoietic stem cell transplants in patients with blood cancers • Source: Shutterstock

More from New Products

More from Scrip